The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Open accessAbstract
We have developed a series of cyclic amine-containing benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system. These compounds exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency. These efforts led to the identification of 3a (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clinical trials. Compound 3a displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a K(i) of 5 nM and in a C41 whole cell assay with an EC(50) of 2 nM. In addition, 3a is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Frye, R. A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0897 · Cited by 807
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Self-citationMenear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Physiology and pathophysiology of poly(ADP‐ribosyl)ation *
Bürkle, A. (2001) · BioEssays · doi:10.1002/bies.1115 · Cited by 335
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Thomas, H. D., Calabrese, C. R., Batey, M. A., Canan, S., Hostomsky, Z., Kyle, S., Maegley, K. A., Newell, D. R., Skalitzky, D., Wang, L.-Z., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0552 · Cited by 303
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., Wang, H., Sandler, A., Johnson, D. H., Colevas, A. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2872 · Cited by 266
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204
Chemopotentiation by PARP inhibitors in cancer therapy
Tentori, L., & Graziani, G. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.010 · Cited by 192
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Inhibition of poly(ADP-ribose) polymerase in cancer
Plummer, E. R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.02.004 · Cited by 106
PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis
Muñoz‐Gámez, J. A., Martín‐Oliva, D., Aguilar‐Quesada, R., et al. (2005) · Biochemical Journal · doi:10.1042/bj20040776 · Cited by 94
Costantino, G., Macchiarulo, A., Camaioni, E., & Pellicciari, R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010116l · Cited by 93
Griffin, R., Curtin, N. J., Newell, D. R., Golding, B. T., Durkacz, B. W., & Calvert, H. (1995) · Biochimie · doi:10.1016/0300-9084(96)88154-5 · Cited by 91
Ishida, J., Yamamoto, H., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Ohkubo, M., Kinoshita, T., Warizaya, M., Iwashita, A., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.061 · Cited by 87
Jagtap, P. G., Baloglu, E., Southan, G. J., Mabley, J. G., Li, H., Zhou, J., van Duzer, J., Salzman, A. L., & Szabó, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502891 · Cited by 82
Penning, T. D., Zhu, G., Gandhi, V. B., Gong, J., Thomas, S. A., Lubisch, W., Grandel, R., Wernet, W., Park, C. H., Fry, E. H., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.044 · Cited by 78
Self-citationShimizu, S., Nomura, F., Tomonaga, T., Sunaga, M., Noda, M., Ebara, M., & Saisho, H. (2004) · Oncology Reports · doi:10.3892/or.12.4.821 · Cited by 71
Ferraris, D. V., Ficco, R. P., Dain, D., Ginski, M. J., Lautar, S. L., Lee-Wisdom, K., Shi, L., Lin, Q., Lu, M. X.-C., Morgan, L. A., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00333-x · Cited by 56
Cited by
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Mouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
Metadata
- Authors
- Penning, T. D., Zhu, G.-D., Gandhi, V. B., Gong, J., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., Donawho, C. K., Frost, D. J., Bontcheva-Diaz, V., Bouska, J. J., Osterling, D. J., Olson, A. M., Marsh, K. C., Luo, Y., & Giranda, V. L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-12-22
- Volume
- 52
- Issue
- 2
- Pages
- 514-523
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2072471623
- Cited by
- 268
- References
- 23
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.